
SEL120-34A hydrochloride
CAS No. 1609452-30-3
SEL120-34A hydrochloride( SEL 120-34A )
Catalog No. M12317 CAS No. 1609452-30-3
SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 115 | Get Quote |
![]() ![]() |
10MG | 192 | Get Quote |
![]() ![]() |
25MG | 323 | Get Quote |
![]() ![]() |
50MG | 482 | Get Quote |
![]() ![]() |
100MG | 687 | Get Quote |
![]() ![]() |
500MG | 1395 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameSEL120-34A hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionSEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
-
DescriptionSEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively; shows no significant inhibition on other members of the CDK family (200-fold over CDK9); inhibits phosphorylation of STAT1 S727 and STAT5 S726 in cancer cells, inhibits IFN- responsive genes expression in vitro; exhibits complete inhibitions of STAT1 S727 and STAT5 S726 in Colo-205 CRC xenograft tissues in mice (60mg/kg).
-
In VitroSEL120-34A HCl is a selective, ATP-competitive CDK8 inhibitor, with IC50 of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively. SEL120-34A HCl shows no obvious inhibition on CDK1, 2, 4, 6, 5, 7, and only weakly suppresses CDK9 (IC50, 1070 nM). SEL120-34A HCl is active against a panel of AML cell lines (GI50<1 μM), such as SKNO-1, KG-1, HEL-60, MOLM-16, MV-4-11, OciAML-2, MOLM-6 and OciAML-3 cells, consistent with the effective inhibition range of STAT1 S727 and STAT5 S726.
-
In VivoSEL120-34A (30, 60 mg/kg, p.o.) inhibits the growth of tumor in mice bearing MV4-11 cancer cells, and also arrests the growth of KG-1-derived tumors at 30 mg/kg via oral administration.
-
SynonymsSEL 120-34A
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1609452-30-3
-
Formula Weight450.6
-
Molecular FormulaC15H19Br2ClN4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 62.5 mg/mL
-
SMILESCC1=C2C3=C(CCCN3C(=N2)N4CCNCC4)C(=C1Br)Br.Cl
-
Chemical Name7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rzymski T, et al. Oncotarget. 2017 May 16;8(20):33779-33795.
molnova catalog



related products
-
(R)-CR8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
M2I-1
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
-
Cdc7 inhibitor
Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.